Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 192

Similar articles for PubMed (Select 18473969)

1.

Review: recent clinical trials in epigenetic therapy.

Oki Y, Issa JP.

Rev Recent Clin Trials. 2006 May;1(2):169-82. Review.

PMID:
18473969
2.

Current status of epigenetic treatment in myelodysplastic syndromes.

Kuendgen A, Lübbert M.

Ann Hematol. 2008 Aug;87(8):601-11. doi: 10.1007/s00277-008-0477-9. Epub 2008 Apr 5. Review.

PMID:
18392623
3.

Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.

Joeckel TE, Lübbert M.

Semin Hematol. 2012 Oct;49(4):330-41. doi: 10.1053/j.seminhematol.2012.08.001. Review.

PMID:
23079063
4.

Decitabine.

Daskalakis M, Blagitko-Dorfs N, Hackanson B.

Recent Results Cancer Res. 2010;184:131-57. doi: 10.1007/978-3-642-01222-8_10. Review.

PMID:
20072836
5.

Epigenetic therapy with decitabine for myelodysplasia and leukemia.

Wijermans P, Lübert M.

Future Oncol. 2005 Oct;1(5):585-91. Review.

PMID:
16556035
6.

Use of hypomethylating agents in myelodysplastic syndromes.

Atallah E, Garcia-Manero G.

Clin Adv Hematol Oncol. 2007 Jul;5(7):544-52. Review.

PMID:
17679928
7.

The role of decitabine in the treatment of myelodysplastic syndromes.

Atallah E, Kantarjian H, Garcia-Manero G.

Expert Opin Pharmacother. 2007 Jan;8(1):65-73. Review.

PMID:
17163808
8.

Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.

Leone G, Voso MT, Teofili L, Lübbert M.

Clin Immunol. 2003 Oct;109(1):89-102. Review.

PMID:
14585280
9.

Decitabine: 2'-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716.

[No authors listed]

Drugs R D. 2003;4(3):179-84. Review.

PMID:
12757405
10.

Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.

Silverman LR, Mufti GJ.

Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S12-23. Review.

PMID:
16341236
11.

5-Azacytidine/Azacitidine.

Müller A, Florek M.

Recent Results Cancer Res. 2010;184:159-70. doi: 10.1007/978-3-642-01222-8_11. Review.

PMID:
20072837
12.

Demethylating agents in myeloid malignancies.

Garcia-Manero G.

Curr Opin Oncol. 2008 Nov;20(6):705-10. doi: 10.1097/CCO.0b013e328313699c. Review.

13.

DNA methyltransferases as targets for cancer therapy.

Ghoshal K, Bai S.

Drugs Today (Barc). 2007 Jun;43(6):395-422. Review.

PMID:
17612710
14.

Clinical experience with decitabine in North American patients with myelodysplastic syndrome.

Yee KW, Jabbour E, Kantarjian HM, Giles FJ.

Ann Hematol. 2005 Dec;84 Suppl 1:18-24.

PMID:
16273408
15.

[Hypomethylating agents for the treatment of myelodysplastic syndromes].

Itzykson R, Fenaux P.

Bull Cancer. 2011 Aug;98(8):927-34. doi: 10.1684/bdc.2011.1411. Review. French.

PMID:
21821482
16.

Decitabine in the treatment of myelodysplastic syndromes.

Santos FP, Kantarjian H, Garcia-Manero G, Issa JP, Ravandi F.

Expert Rev Anticancer Ther. 2010 Jan;10(1):9-22. doi: 10.1586/era.09.164. Review.

PMID:
20014881
17.

Clinical development of decitabine as a prototype for an epigenetic drug program.

Rosenfeld CS.

Semin Oncol. 2005 Oct;32(5):465-72. Review.

PMID:
16210087
18.

[Demethylating medication in myelodysplastic syndrome].

Manson ML, Derissen EJ, Wijermans PW, Schellens JH, Beijnen JH.

Ned Tijdschr Geneeskd. 2012;156(4):A3167. Review. Dutch.

PMID:
22278034
19.

DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.

Griffiths EA, Gore SD.

Semin Hematol. 2008 Jan;45(1):23-30. doi: 10.1053/j.seminhematol.2007.11.007. Review.

20.

Decitabine.

Issa JP.

Curr Opin Oncol. 2003 Nov;15(6):446-51. Review.

PMID:
14624227
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk